Atypical hemolytic uremic syndrome post-kidney transplantation: Two case reports and review of the literature

Frontiers in Medicine

Volumn 1, Issue DEC, 2014, Pages

  Alasfar, Sami ^a   Alachkar, Nada ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

aHUS; Eculizumab; Genetic mutation; Kidney transplant; Recurrence

Indexed keywords

EID: 84947130293     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2014.00052     Document Type: Review

References (112)

1. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med (2009) 361:1676-87. doi: 10.1056/NEJMra0902814
2. Salvadori M, Bertoni E. Update on hemolytic uremic syndrome: diagnostic and therapeutic recommendations. World J Nephrol (2013) 2:56-76. doi:10.5527/wjn.v2.i3.56
3. O'Brien AO, Lively TA, Chen ME, Rothman SW, Formal SB. Escherichia coli O157:H7 strains associated with haemorrhagic colitis in the United States produce a Shigella dysenteriae 1 (SHIGA) like cytotoxin. Lancet (1983) 1(8326 Pt 1):702. doi:10.1016/S0140-6736(83)91987-6
4. Lemaire M, Frémeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet (2013) 45:531-6. doi:10.1038/ng.2590
5. Zuber J, Le Quintrec M, Morris H, Frémeaux-Bacchi V, Loirat C, Legendre C. Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transplant Rev (Orlando) (2013) 27:117-25. doi:10.1016/j.trre.2013.07.003
6. Cameron JS, Vick R. Letter: plasma-C3 in haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura. Lancet (1973) 2:975. doi:10.1016/S0140-6736(73)92645-7
7. Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Frémeaux-Bacchi V, Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol (2011) 7:23-35. doi:10.1038/nrneph.2010.155
8. Skerka C, Chen Q, Fremeaux-Bacchi V, Roumenina LT. Complement factor H related proteins (CFHRs). Mol Immunol (2013) 56:170-80. doi:10.1016/j.molimm.2013.06.001
9. Joseph C, Gattineni J. Complement disorders and hemolytic uremic syndrome. Curr Opin Pediatr (2013) 25:209-15. doi:10.1097/MOP.0b013e32835df48a
10. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA, Garrido CA, et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A (2007) 104:240-5. doi:10.1073/pnas.0603420103
11. Frémeaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J, Brown AL, et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood (2008) 112:4948-52. doi:10.1182/blood-2008-01-133702
12. Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med (2009) 361:345-57. doi:10.1056/NEJMoa0810739
13. Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, Carreras Berges L, López-Trascasa M, Sánchez-Corral P, et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet (2005) 14:703-12. doi:10.1093/hmg/ddi099
14. Esparza-Gordillo J, Jorge EG, Garrido CA, Carreras L, López-Trascasa M, Sánchez-Corral P, et al. Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol Immunol (2006) 43:1769-75. doi:10.1016/j.molimm.2005.11.008
15. Fremeaux-Bacchi V, Kemp EJ, Goodship JA, Dragon-Durey MA, Strain L, Loirat C, et al. The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts. J Med Genet (2005) 42:852-6. doi:10.1136/jmg.2005.030783
16. Rodriguez E, Rallapalli PM, Osborne AJ, Perkins SJ. New functional and structural insights from updated mutational databases for complement factor H, factor I, membrane cofactor protein and C3. Biosci Rep (2014) 34(5):e00146. doi:10.1042/BSR20140117
17. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood (2006) 108:1267-79. doi:10.1182/blood-2005-10-007252
18. Caprioli J, Bettinaglio P, Zipfel PF, Amadei B, Daina E, Gamba S, et al. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol (2001) 12:297-307
19. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol (2010) 5:1844-59. doi:10.2215/CJN.02210310
20. Kavanagh D, Kemp EJ, Mayland E, Winney RJ, Duffield JS, Warwick G, et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol (2005) 16:2150-5. doi:10.1681/ASN.2005010103
21. Kavanagh D, Richards A, Noris M, Hauhart R, Liszewski MK, Karpman D, et al. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol (2008) 45:95-105. doi:10.1016/j.molimm.2007.05.004
22. Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood (2010) 115:379-87. doi:10.1182/blood-2009-05-221549
23. Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, et al. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol (2013) 8:407-15. doi:10.2215/CJN.01260212
24. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2007) 18:2392-400. doi:10.1681/ASN.2006080811
25. Richards A, Kemp EJ, Liszewski MK, Goodship JA, Lampe AK, Decorte R, et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A (2003) 100:12966-71. doi:10.1073/pnas.2135497100
26. Bienaime F, Dragon-Durey MA, Regnier CH, Nilsson SC, Kwan WH, Blouin J, et al. Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int (2010) 77:339-49. doi:10.1038/ki.2009.472
27. Noris M, Bresin E, Mele C, Remuzzi G. Atypical hemolytic-uremic syndrome. In: Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong C-T, et al. editors. GeneReviews® [Internet]. Seattle, WA: University of Washington; 1993-2014 (2013). p. 9-26
28. Nilsson SC, Kalchishkova N, Trouw LA, Fremeaux-Bacchi V, Villoutreix BO, Blom AM. Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I. Eur J Immunol (2010) 40:172-85. doi:10.1002/eji.200939280
29. Sinibaldi S, Guzzo I, Piras R, Bresin E, Emma F, Dello Strologo L. Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation. Pediatr Transplant (2013) 17:E177-81. doi:10.1111/petr.12151
30. Tawadrous H, Maga T, Sharma J, Kupferman J, Smith RJ, Schoeneman M. A novel mutation in the complement factor B gene (CFB) and atypical hemolytic uremic syndrome. Pediatr Nephrol (2010) 25:947-51. doi:10.1007/s00467-009-1415-3
31. Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis (2011) 6:60. doi:10.1186/1750-1172-6-60
32. Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol (2008) 23:1957-72. doi:10.1007/s00467-008-0872-4
33. Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat (2010) 31:E1445-60. doi:10.1002/humu.21256
34. Martinez-Barricarte R, Pianetti G, Gautard R, Misselwitz J, Strain L, Fremeaux-Bacchi V, et al. The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol (2008) 19:639-46. doi:10.1681/ASN.2007080923
35. Abarrategui-Garrido C, Martínez-Barricarte R, López-Trascasa M, de Córdoba SR, Sánchez-Corral P. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood (2009) 114:4261-71. doi:10.1182/blood-2009-05-223834
36. Skerka C, Zipfel PF. Complement factor H related proteins in immune diseases. Vaccine (2008) 26(Suppl 8):I9-14. doi:10.1016/j.vaccine.2008.11.021
37. Venables JP, Strain L, Routledge D, Bourn D, Powell HM, Warwicker P, et al. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med (2006) 3:e431. doi:10.1371/journal.pmed.0030431
38. Francis NJ, McNicholas B, Awan A, Waldron M, Reddan D, Sadlier D, et al. A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome. Blood (2012) 119:591-601. doi:10.1182/blood-2011-03-339903
39. Józsi M, Licht C, Strobel S, Zipfel SL, Richter H, Heinen S, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood (2008) 111:1512-4. doi:10.1182/blood-2007-09-109876
40. Dragon-Durey MA, Blanc C, Marliot F, Loirat C, Blouin J, Sautes-Fridman C, et al. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet (2009) 46:447-50. doi:10.1136/jmg.2008.064766
41. Zipfel PF, Mache C, Müller D, Licht C, Wigger M, Skerka C, et al. DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome. Pediatr Nephrol (2010) 25:2009-19. doi:10.1007/s00467-010-1446-9
42. Westra D, Wetzels JF, Volokhina EB, van den Heuvel LP, van de Kar NC. A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome. Neth J Med (2012) 70:121-9
43. Loirat C, Niaudet P. The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children. Pediatr Nephrol (2003) 18:1095-101. doi:10.1007/s00467-003-1289-8
44. Hébert D, Kim EM, Sibley RK, Mauer MS. Post-transplantation outcome of patients with hemolytic-uremic syndrome: update. Pediatr Nephrol (1991) 5:162-7. doi:10.1007/BF00852876
45. Hebert D, Sibley RK, Mauer SM. Recurrence of hemolytic uremic syndrome in renal transplant recipients. Kidney Int Suppl (1986) 19:S51-8
46. Artz MA, Steenbergen EJ, Hoitsma AJ, Monnens LA, Wetzels JF. Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections. Transplantation (2003) 76:821-6. doi:10.1097/01.TP.0000085083.74065.1B
47. Lahlou A, Lang P, Charpentier B, Barrou B, Glotz D, Baron C, et al. Hemolytic uremic syndrome. Recurrence after renal transplantation. Groupe Cooperatif de l'Ile-de-France (GCIF). Medicine (Baltimore) (2000) 79:90-102. doi:10.1097/00005792-200003000-00003
48. Quan A, Sullivan EK, Alexander SR. Recurrence of hemolytic uremic syndrome after renal transplantation in children: a report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation (2001) 72:742-5. doi:10.1097/00007890-200108270-00033
49. Bresin E, Daina E, Noris M, Castelletti F, Stefanov R, Hill P, et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol (2006) 1:88-99. doi:10.2215/CJN.00050505
50. Loirat C, Fremeaux-Bacchi V. Hemolytic uremic syndrome recurrence after renal transplantation. Pediatr Transplant (2008) 12:619-29. doi:10.1111/j.1399-3046.2008.00910.x
51. Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant (2013) 13:663-75. doi:10.1111/ajt.12077
52. Kwon T, Dragon-Durey MA, Macher MA, Baudouin V, Maisin A, Peuchmaur M, et al. Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome. Nephrol Dial Transplant (2008) 23:2088-90. doi:10.1093/ndt/gfn063
53. Le Quintrec M, Zuber J, Noel LH, Thervet E, Frémeaux-Bacchi V, Niaudet P, et al. Anti-Factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome. Am J Transplant (2009) 9:1223-9. doi:10.1111/j.1600-6143.2009.02586.x
54. Waters AM, Pappworth I, Marchbank K, Bockenhauer D, Tullus K, Pickering MC, et al. Successful renal transplantation in factor H autoantibody associated HUS with CFHR1 and 3 deficiency and CFH variant G2850T. Am J Transplant (2010) 10:168-72. doi:10.1111/j.1600-6143.2009.02870.x
55. Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, Vigneau C, Kuypers D, Boudailliez B, et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet (2004) 41:e84. doi:10.1136/jmg.2004.019083
56. Chan MR, Thomas CP, Torrealba JR, Djamali A, Fernandez LA, Nishimura CJ, et al. Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipient. Am J Kidney Dis (2009) 53:321-6. doi:10.1053/j.ajkd.2008.06.027
57. Geelen J, van den Dries K, Roos A, van de Kar N, de Kat Angelino C, Klasen I, et al. A missense mutation in factor I (IF) predisposes to atypical haemolytic uraemic syndrome. Pediatr Nephrol (2007) 22:371-5. doi:10.1007/s00467-006-0320-2
58. Nilsson SC, Karpman D, Vaziri-Sani F, Kristoffersson AC, Salomon R, Provot F, et al. A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. Mol Immunol (2007) 44:1835-44. doi:10.1016/j.molimm.2006.10.005
59. Davin JC, Buter N, Groothoff J, van Wijk J, Bouts A, Strain L, et al. Prophylactic plasma exchange in CD46-associated atypical haemolytic uremic syndrome. Pediatr Nephrol (2009) 24:1757-60. doi:10.1007/s00467-009-1188-8
60. Fremeaux-Bacchi V, Moulton EA, Kavanagh D, Dragon-Durey MA, Blouin J, Caudy A, et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2006) 17:2017-25. doi:10.1681/ASN.2005101051
61. Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, et al. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol (2013) 24:475-86. doi:10.1681/ASN.2012090884
62. Matar D, Naqvi F, Racusen LC, Carter-Monroe N, Montgomery RA, Alachkar N. Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation (2014) 98(11):1205-12. doi:10.1097/TP.0000000000000200
63. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med (2002) 8:582-7. doi:10.1038/nm0602-582
64. Zheng X, Feng B, Chen G, Zhang X, Li M, Sun H, et al. Preventing renal ischemia-reperfusion injury using small interfering RNA by targeting complement 3 gene. Am J Transplant (2006) 6:2099-108. doi:10.1111/j.1600-6143.2006.01427.x
65. Roumenina LT, Jablonski M, Hue C, Blouin J, Dimitrov JD, Dragon-Durey MA, et al. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood (2009) 114:2837-45. doi:10.1182/blood-2009-01-197640
66. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey MA, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol (2013) 8:554-62. doi:10.2215/CJN.04760512
67. Ducloux D, Rebibou JM, Semhoun-Ducloux S, Jamali M, Fournier V, Bresson-Vautrin C, et al. Recurrence of hemolytic-uremic syndrome in renal transplant recipients: a meta-analysis. Transplantation (1998) 65:1405-7. doi:10.1097/00007890-199805270-00023
68. Naesens M, Li L, Ying L, Sansanwal P, Sigdel TK, Hsieh SC, et al. Expression of complement components differs between kidney allografts from living and deceased donors. J Am Soc Nephrol (2009) 20:1839-51. doi:10.1681/ASN.2008111145
69. van Werkhoven MB, Damman J, van Dijk MC, Daha MR, de Jong IJ, Leliveld A, et al. Complement mediated renal inflammation induced by donor brain death: role of renal C5a-C5aR interaction. Am J Transplant (2013) 13:875-82. doi:10.1111/ajt.12130
70. Snoeijs MG, Vink H, Voesten N, Christiaans MH, Daemen JW, Peppelenbosch AG, et al. Acute ischemic injury to the renal microvasculature in human kidney transplantation. Am J Physiol Renal Physiol (2010) 299:F1134-40. doi:10.1152/ajprenal.00158.2010
71. Olie KH, Goodship TH, Verlaak R, Florquin S, Groothoff JW, Strain L, et al. Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: successful treatment with intensive plasma exchanges and ganciclovir. Am J Kidney Dis (2005) 45:e12-5. doi:10.1053/j.ajkd.2004.09.012
72. Al-Akash SI, Almond PS, Savell VH Jr, Gharaybeh SI, Hogue C. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol (2011) 26:613-9. doi:10.1007/s00467-010-1708-6
73. Printza N, Roilides E, Kotsiou M, Zafeiriou D, Hatzidimitriou V, Papachristou F. Pandemic influenza A (H1N1) 2009-associated hemolytic uremic syndrome. Pediatr Nephrol (2011) 26:143-4. doi:10.1007/s00467-010-1603-1
74. Trachtman H, Sethna C, Epstein R, D'Souza M, Rubin LG, Ginocchio CC. Atypical hemolytic uremic syndrome associated with H1N1 influenza A virus infection. Pediatr Nephrol (2011) 26:145-6. doi:10.1007/s00467-010-1636-5
75. Murer L, Zacchello G, Bianchi D, Dall'Amico R, Montini G, Andreetta B, et al. Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation. J Am Soc Nephrol (2000) 11:1132-7
76. Petrogiannis-Haliotis T, Sakoulas G, Kirby J, Koralnik IJ, Dvorak AM, Monahan-Earley R, et al. BK-related polyomavirus vasculopathy in a renal-transplant recipient. N Engl J Med (2001) 345:1250-5. doi:10.1056/NEJMoa010319
77. Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol (2011) 26:1325-9. doi:10.1007/s00467-011-1879-9
78. Nester C, Stewart Z, Myers D, Jetton J, Nair R, Reed A, et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol (2011) 6:1488-94. doi:10.2215/CJN.10181110
79. Al-Massarani G, Vacher-Coponat H, Paul P, Widemann A, Arnaud L, Loundou A, et al. Impact of immunosuppressive treatment on endothelial biomarkers after kidney transplantation. Am J Transplant (2008) 8:2360-7. doi:10.1111/j.1600-6143.2008.02399.x
80. Miriuka SG, Rao V, Peterson M, Tumiati L, Delgado DH, Mohan R, et al. mTOR inhibition induces endothelial progenitor cell death. Am J Transplant (2006) 6:2069-79. doi:10.1111/j.1600-6143.2006.01433.x
81. Ponticelli C. De novo thrombotic microangiopathy. An underrated complication of renal transplantation. Clin Nephrol (2007) 67:335-40. doi:10.5414/CNP67335
82. Le Quintrec M, Lionet A, Kamar N, Karras A, Barbier S, Buchler M, et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant (2008) 8:1694-701. doi:10.1111/j.1600-6143.2008.02297.x
83. Schwimmer J, Nadasdy TA, Spitalnik PF, Kaplan KL, Zand MS. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis (2003) 41:471-9. doi:10.1053/ajkd.2003.50058
84. Wilson CH, Brown AL, White SA, Goodship TH, Sheerin NS, Manas DM. Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab. Transplantation (2011) 92:e42-3. doi:10.1097/TP.0b013e318230c0bd
85. Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program (2004) 2004(1):407-23. doi:10.1182/asheducation-2004.1.407
86. Gandhi K, Aronow WS, Desai H, Amin H, Sharma M, Lai HM, et al. Cardiovascular manifestations in patients with thrombotic thrombocytopenic purpura: a single-center experience. Clin Cardiol (2010) 33:213-6. doi:10.1002/clc.20731
87. Olie KH, Florquin S, Groothoff JW, Verlaak R, Strain L, Goodship TH, et al. Atypical relapse of hemolytic uremic syndrome after transplantation. Pediatr Nephrol (2004) 19:1173-6. doi:10.1007/s00467-004-1565-2
88. Stevenson S, Mallett A, Oliver K, Hyland V, Hawley C, Malmanche T, et al. Atypical HUS associated with severe, unexpected antibody-mediated rejection post kidney transplant. Nephrology (Carlton) (2014) 19(Suppl 1):22-6. doi:10.1111/nep.12195
89. Noone D, Al-Matrafi J, Tinckam K, Zipfel PF, Herzenberg AM, Thorner PS, et al. Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab. Am J Transplant (2012) 12:2546-53. doi:10.1111/j.1600-6143.2012.04124.x
90. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V, French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol (2012) 8:643-57. doi:10.1038/nrneph.2012.214
91. Davin JC, Strain L, Goodship TH. Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Pediatr Nephrol (2008) 23:1517-21. doi:10.1007/s00467-008-0833-y
92. Loirat C, Saland J, Bitzan M. Management of hemolytic uremic syndrome. Presse Med (2012) 41(3 Pt 2):e115-35. doi:10.1016/j.lpm.2011.11.013
93. Remuzzi G, Ruggenenti P, Codazzi D, Noris M, Caprioli J, Locatelli G, et al. Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet (2002) 359:1671-2. doi:10.1016/S0140-6736(02)08560-4
94. Remuzzi G, Ruggenenti P, Colledan M, Gridelli B, Bertani A, Bettinaglio P, et al. Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation. Am J Transplant (2005) 5:1146-50. doi:10.1111/j.1600-6143.2005.00783.x
95. Lennon FE, Singleton PA. Hyaluronan regulation of vascular integrity. Am J Cardiovasc Dis (2011) 1:200-13
96. Rehm M, Bruegger D, Christ F, Conzen P, Thiel M, Jacob M, et al. Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation (2007) 116:1896-906. doi:10.1161/CIRCULATIONAHA.106.684852
97. Saland J. Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab? Pediatr Nephrol (2014) 29:329-32. doi:10.1007/s00467-013-2722-2
98. Zuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant (2012) 12:3337-54. doi:10.1111/j.1600-6143.2012.04252.x
99. Chatelet V, Frémeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant (2009) 9:2644-5. doi:10.1111/j.1600-6143.2009.02817.x
100. Koskinen AR, Tukiainen E, Arola J, Nordin A, Höckerstedt HK, Nilsson B, et al. Complement activation during liver transplantation-special emphasis on patients with atypical hemolytic uremic syndrome. Am J Transplant (2011) 11:1885-95. doi:10.1111/j.1600-6143.2011.03612.x
101. de Vries DK, van der Pol P, van Anken GE, van Gijlswijk DJ, Damman J, Lindeman JH, et al. Acute but transient release of terminal complement complex after reperfusion in clinical kidney transplantation. Transplantation (2013) 95:816-20. doi:10.1097/TP.0b013e31827e31c9
102. Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood (2011) 117:6786-92. doi:10.1182/blood-2011-02-333997
103. de Jorge EG, Macor P, Paixão-Cavalcante D, Rose KL, Tedesco F, Cook HT, et al. The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol (2011) 22:137-45. doi:10.1681/ASN.2010050451
104. Nurnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med (2009) 360:542-4. doi:10.1056/NEJMc0808527
105. Larrea CF, Cofan F, Oppenheimer F, Campistol JM, Escolar G, Lozano M. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation (2010) 89:903-4. doi:10.1097/TP.0b013e3181ccd80d
106. Alachkar N, Bagnasco SM, Montgomery RA. Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft. Transpl Int (2012) 25:e93-5. doi:10.1111/j.1432-2277.2012.01497.x
107. Legendre C, Sberro-Soussan R, Zuber J, Rabant M, Loupy A, Timsit MO, et al. Eculizumab in renal transplantation. Transplant Rev (Orlando) (2013) 27:90-2. doi:10.1016/j.trre.2013.04.002
108. Davin JC, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis (2010) 55:708-11. doi:10.1053/j.ajkd.2009.08.011
109. Miller RB, Burke BA, Schmidt WJ, Gillingham KJ, Matas AJ, Mauer M, et al. Recurrence of haemolytic-uraemic syndrome in renal transplants: a single-centre report. Nephrol Dial Transplant (1997) 12:1425-30. doi:10.1093/ndt/12.7.1425
110. Xie L, Nester CM, Reed AI, Zhang Y, Smith RJ, Thomas CP. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report. Transplant Proc (2012) 44:3037-40. doi:10.1016/j.transproceed.2012.07.141
111. Sakai M, Ikezoe T, Bandobashi K, Togitani K, Yokoyama A. Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin. Bone Marrow Transplant (2010) 45:803-5. doi:10.1038/bmt.2009.242
112. Wagner E, Frank MM. Therapeutic potential of complement modulation. Nat Rev Drug Discov (2010) 9:43-56. doi:10.1038/nrd3011